KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $903.5 million.

  • Ionis Pharmaceuticals' Total Current Liabilities rose 196.64% to $903.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.5 million, marking a year-over-year increase of 196.64%. This contributed to the annual value of $309.3 million for FY2024, which is 30.97% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Total Current Liabilities stood at $903.5 million, which was up 0.69% from $897.2 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Total Current Liabilities' 5-year high stood at $903.5 million during Q3 2025, with a 5-year trough of $228.4 million in Q1 2022.
  • In the last 3 years, Ionis Pharmaceuticals' Total Current Liabilities had a median value of $309.3 million in 2024 and averaged $427.1 million.
  • In the last 5 years, Ionis Pharmaceuticals' Total Current Liabilities crashed by 59.83% in 2021 and then skyrocketed by 196.64% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $240.6 million in 2021, then grew by 29.52% to $311.6 million in 2022, then spiked by 43.82% to $448.1 million in 2023, then tumbled by 30.97% to $309.3 million in 2024, then skyrocketed by 196.64% to $903.5 million in 2025.
  • Its Total Current Liabilities stands at $903.5 million for Q3 2025, versus $897.2 million for Q2 2025 and $250.3 million for Q1 2025.